Arvinas, Inc. · NASDAQ:ARVN

Arvinas — San Antonio Breast Cancer Symposium 2016

11 slides from Arvinas's conference presentation, December 2016

  1. Slide 1: Targeted and Selective Degradation of ERa by PROTACs

    San Antonio Breast Cancer Symposium, December 6-10, 2016 Targeted and Selective Degradation of ERa by PROTACs John J. Flanagan, Yimin Qian, Ann Marie K. Rossi, Monica Andreoli, Ryan Willard, Deborah Gordon, John Harling, Ian Churcher, Ian Smith, Nico Zinn, Marcus Bantscheff, Craig M. Crews, Ian Tayl

  2. Slide 2: PROTAC: PROteolysis TArgeting Chimera

    San Antonio Breast Cancer Symposium, December 6-10, 2016 PROTAC: PROteolysis TArgeting Chimera  Chimeric, small molecule PROTACs recruit E3 ligase to target proteins to promote polyubiquitination and induce their degradation via the proteasome PROTAC Ubiquitin Ligand for E3 ligase target protein re

  3. Slide 3: PROTAC potently reduces ERa levels in T47D cells

    San Antonio Breast Cancer Symposium, December 6-10, 2016 PROTAC potently reduces ERa levels in T47D cells DMSO DMSO DMSO Fulvestrant PROTAC A RAD1901 AZD9496 GDC810 Inactive PROTAC ERa %ERa 73% 78% 20% 10% 23% None • Robust degradation of ERa with PROTACs and fulvestrant in other ER+ cell lines (BT4

  4. Slide 4: PROTAC reduces ERa levels in nuclear fractions

    San Antonio Breast Cancer Symposium, December 6-10, 2016 PROTAC reduces ERa levels in nuclear fractions Cytosolic Nuclear Soluble Nuclear Pellet GAPDH Histone H3 MCM2 ERa T47D cells 72-hours 5% CSS 100 nM 4 Contact John.Flanagan@arvinas.com for permission to reprint and/or distribute this presentati

  5. Slide 5: Greater anti-proliferative effects with ERa degraders

    San Antonio Breast Cancer Symposium, December 6-10, 2016 Greater anti-proliferative effects with ERa degraders DMSO FULV PROTAC A AZD9496 SERD GDC810 P e rc e n t A re a o f G ro w th 20 15 T47D cells 20 days 10 10% FBS 100 nM 5 0 5 Contact John.Flanagan@arvinas.com for permission to reprint and/or

  6. Slide 6: Selective degradation of ERa by PROTACs

    San Antonio Breast Cancer Symposium, December 6-10, 2016 Selective degradation of ERa by PROTACs ERa PROTAC A (500 nM) Inactive ERa PROTAC (500 nM) ERa Rel. abundance (log2) Replicate 2 RRM2 RRM2 ESCO2 ESCO2 ERa PRSS23 PRSS23 GREB1 GREB1 Rel. abundance (log2) Rel. abundance (log2) Replicate 1 Replic

  7. Slide 7: ERa PROTAC inhibits growth of MCF7 xenografts

    San Antonio Breast Cancer Symposium, December 6-10, 2016 ERa PROTAC inhibits growth of MCF7 xenografts • 21-day growth study 800 V e h ic le • 68% TGI achieved with F u lv e s tr a n t ( 2 0 0 m p k , q w , s c ) T u m o r v o lu m e ( m m ) 3 P R O T A C A (3 0 m p k , q d , s c ) daily 30 mpk PROT

  8. Slide 8: PROTAC decreases ERa levels in MCF7 xenografts

    San Antonio Breast Cancer Symposium, December 6-10, 2016 PROTAC decreases ERa levels in MCF7 xenografts Control MCF7 Vehicle PROTAC A , 30 mpk lysate ERa GAPDH • ~60% reduction in ERa levels with PROTAC A (30 mpk, s.c.) • Tumors were harvested four hours post-dose 8 Contact John.Flanagan@arvinas.com

  9. Slide 9: ERa degradation after oral administration of PROTAC

    San Antonio Breast Cancer Symposium, December 6-10, 2016 ERa degradation after oral administration of PROTAC 1.5 10 6 n=5 - 50% • MCF7-estradiol AVGSD - 61% ERa Levels (AU) deprived cells 1 10 6 implanted in adult female 5 10 5 mice • Similar reduction 0 Vehicle Fulvestrant Vehicle PROTAC B of E

  10. Slide 10: Summary

    San Antonio Breast Cancer Symposium, December 6-10, 2016 Summary • PROTAC-mediated degradation provides a distinct mechanism for reducing ERa when compared to fulvestrant and current clinical SERDs • PROTACs reduce ERa levels in all ER+ cell lines tested • Oral administration of PROTACs reduced ERa

  11. Slide 11: Targeted and Selective Degradation of ERa by PROTACs

    San Antonio Breast Cancer Symposium, December 6-10, 2016 Targeted and Selective Degradation of ERa by PROTACs John J. Flanagan, Yimin Qian, Ann Marie K. Rossi, Monica Andreoli, Ryan Willard, Deborah Gordon, John Harling, Ian Churcher, Ian Smith, Nico Zinn, Marcus Bantscheff, Craig M. Crews, Ian Tayl

Arvinas — San Antonio Breast Cancer Symposium 2016 on 6ix